Objective: Recombinant humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody is an innovative drug developed by China. In the clinical trial of healthy people, the innovative drug showed fairly good safety and tolerance. Model-informed drug development (MIDD) is widely used in innovative drug development. It has an important practical value in improving efficiency, predicting drug interactions, and optimizing dosage. Therefore, we aim at providing evidence and support for dose selection and dosing interval of the innovative drug. Methods: A population pharmacokinetics (PopPK) model, dose-exposure-response (D-E-R) analysis, and Monte Carlo simulation would be performed to explore covariates, optimal dose selection, and dosing interval recommendation. Results: Body weight and hemoglobin have an effect on apparent volume of distribution, total bilirubin has an effect on of clearance rate. D-E-R analysis presents that the innovative drug achieves benefit efficacy with 6 mg/kg. Monte Carlo simulation showed that administration every 4 weeks, 6 weeks and 8 weeks has similar drug exposure. Conclusion: Our results demonstrated that the innovative drug administration every 8 weeks with 6 mg/kg is appropriate. It is worth noting that further clinical trials with larger samples needs to be develop to confirm the results.